Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based immunotherapies. The potential for applying T cell-based immunotherapy in the treatment of acute myeloid leukemia (AML) has stimulated interest in analyzing HLA class I antigen expression on leukemic blasts in this disease. Little information is available in the literature. We have analyzed HLA class I antigen expression on bone marrow samples from 25 newly diagnosed AML patients by indirect immunofluorescence staining with monoclonal antibodies. Five of these patients were also studied at relapse. Leukemic blasts were resolved from normal lymphocytes by staining with anti-CD45 antibody; CD45 expression is dim on leukemia cells, but bright on lymphocytes. HLA class I antigen expression was higher on leukemic blasts than on autologous lymphocytes in all but one case. Moreover, there was no significant change in HLA class I antigen expression at relapse. These results suggest that abnormalities in HLA class I antigens are infrequent in AML and should not represent a major obstacle to the application of T cell-based immunotherapies in this disease. Leukemia (2001) 15, 128-133. 
Introduction
Human leukocyte antigen (HLA) class I molecules bind antigenic peptides and present them to T cell receptors. The recognition of these peptides by cytotoxic T cells (CTL) triggers a series of events that may result in lysis of target cells. As a result, HLA class I antigen downregulation in malignant cells, which occurs frequently in solid tumors, 1 may adversely affect both the clinical course of the disease and the outcome of T cell-based immunotherapy. 1 Expression of HLA class I molecules on acute myeloid leukemia (AML) blasts at diagnosis has been analyzed only by Richiardi and colleagues. 2, 3 They initially studied the expression of HLA-A and -B antigens in samples from 34 AML patients by testing with alloantisera in a complement-dependent lymphocytotoxicity assay. Total HLA class I antigen loss was found in eight samples, and selective loss of HLA class I allospecificities was found in eight additional samples. 2 Similar results were obtained by the same group of investigators when they analyzed 33 additional AML samples by indirect immunofluorescence staining with a monoclonal antibody (mAb) which recognizes a monomorphic determinant of HLA class I antigens. 3 Expression of HLA class I antigens at relapse of AML was not studied.
We have studied the expression of HLA class I molecules on the surface of AML blasts by multiparameter flow cytometry at diagnosis and at relapse using monoclonal antibodies which recognize monomorphic, locus-specific and polymorphic determinants of HLA-A, B and C antigens. Our results demonstrate that loss of HLA class I molecules is not a frequent phenomenon in AML.
Materials and methods

Samples
Bone marrow samples were obtained from 25 newly diagnosed AML patients referred to Roswell Park Cancer Institute (RPCI) between May 1994 and June 1999. Viable cells were cryopreserved at diagnosis using standard procedures. Samples were selected for study based on the availability of at least 2 × 10 7 cells. Seven of the patients studied at diagnosis relapsed. Relapse samples were available from five patients, including one who was studied both at first and at second relapse. Relapse occurred at a median of 300 days (range, 182-484 days) in the five patients. Eight bone marrow samples collected from these patients at remission were studied as controls.
Studies were approved by the RPCI Institutional Review Board. Informed consent was obtained from all patients.
Morphologic studies
The diagnosis of AML and morphologic categorization were according to the French-American-British (FAB) classification.
4,5
Cytogenetic analysis
Cytogenetic analysis was performed on pretreatment bone marrow samples from all patients. Samples were processed using short-term unstimulated cultures (24-72 h). Clonality criteria and description of chromosome aberrations were according to the International System for Human Cytogenetic Nomenclature. 6 For purposes of this study, patients were divided into three prognostic groups based on karyotype, as previously described. 7 The prognostic groups were favorable [t (8;21) , inv (16) 
Response criteria
Complete remission (CR) was defined by normalization of blood counts and bone marrow morphology and disappearance of all signs of leukemia, lasting for у4 weeks, in accord-ance with the recommendations of the National Cancer Institute-sponsored workshop. 8 Disease-free survival was defined from the date of attainment of CR to the date of relapse. Relapse was defined as reappearance of blasts in the blood or the finding of у5% blasts in the bone marrow, not attributable to another cause, also in accordance with the recommendations of the National Cancer Institute-sponsored workshop. 8 
Monoclonal and polyclonal antibodies
The mAb TP25.99 which recognizes a determinant expressed on both ␤ 2 microglobulin (␤ 2 M)-associated and ␤ 2 M-free HLA class I heavy chains, 9 the mAbs LGIII-147.4.2 and LGIII-220.6 which recognize determinants restricted to HLA-A antigens (Ferrone et al, unpublished data) , the mAb 4E which recognizes a determinant restricted to HLA-B antigens, 10 the anti-HLA-A2, A28 mAb KS1, 11 the anti-HLA-B7 crossreacting group mAb KS4 12 and the anti-␤ 2 M mAb NAMB-1 13 were developed and characterized as described. Fluorescein isothiocyanate (FITC)-labeled CD45 mAb and phycoerythrin (PE)-labeled goat anti-mouse immunoglobulin (IgG) antibodies were purchased from Becton Dickinson Biosciences (San Diego, CA, USA) and from Caltag (San Francisco, CA, USA), respectively.
Immunophenotypic characterization
Immunophenotyping was performed by multiparameter flow cytometry.
14 Cryopreserved bone marrow cells were thawed in RPMI 1640 medium (Life Technologies, Rockville, MD, USA) supplemented with 2% fetal calf serum (Sigma Immunochemicals, St Louis, MO, USA). Cells were centrifuged at 1500 g for 3 min and the pellet was resuspended in 500 l of phosphate buffered saline (PBS). Fifty l aliquots were distributed into nine 13 × 75 mm tubes and incubated for 15 min on ice with an excess of the anti-HLA class I mAb or an isotype control or no staining control (autofluorescence). Following the addition of the PE-labeled goat anti-mouse IgG antibody, cells were incubated and washed by adding 3 ml of PBS and centrifuging them at 1500 g for 3 min. The pellet was resuspended and cells were blocked with 10 l of a mouse IgG solution (1 mg/ml) for 10 min on ice to saturate all unbound anti-IgG Fab sites. Five microliters of FITC-labeled CD45 antibody were added. Then cells were incubated on ice for 15 min, washed and fixed in 300 l ultrapure formaldehyde. Differences in CD45 expression were used to resolve leukemic cells from normal lymphocytes in each case of AML. Leukemic blasts exhibit dim CD45 expression while CD45 expression on lymphocytes is bright.
Cell viability was determined by ethidium monoazide fluorescence, as previously described 15 and by the trypan blue method. All samples had у85% viable cells in the gated regions and were thus appropriate for analysis, in accordance with the National Committee for Clinical Laboratory Standards guidelines. 16 Forward and side scatter and two colors of fluorescence were measured for each sample on a FACSCaliber flow cytometer (Becton Dickinson Biosciences). Data were analyzed using WinList multiparameter analysis software (Verity Software House, Topsham, ME, USA). In the bivariate display of side scatter vs CD45 expression, a region was drawn around the leukemic cell population, characterized by dim CD45 expression, and a second region was drawn around the Leukemia lymphocytes, characterized by low side scatter and bright CD45 expression. The data were backgated to produce a bivariate display of CD45 expression vs HLA class I antigen expression. New regions were drawn around the cells in this display to resolve leukemic blasts and lymphocytes. The same method was used to resolve the non-leukemic normal myeloid progenitors in remission samples. Percentages of cells, mean channel fluorescence intensities and coefficients of variation were then determined for each population. If lymphocytes were not present in sufficient numbers to be studied in the pretreatment bone marrow sample, a remission bone marrow was analyzed to define the lymphocyte fluorescence intensity (eight patients). We also used these remission samples to study the expression of HLA class I antigens on the non-leukemic normal myeloid progenitor cell population. The leukemic, normal myeloid progenitor and lymphocyte populations in each case were resolved by their patterns of CD45 expression in conjunction with side scatter. Therefore, HLA class I antigen expression on leukemic blasts, normal myeloid progenitors and lymphocytes in each case was defined using three parameters: side scatter, CD45 expression and HLA class I antigen expression. Labeling with isotype control antibodies was performed for all antibodies on all samples and was used to define specific binding.
Statistical section
All comparisons were paired by patient. The differences in the mean channel fluorescence between leukemic blasts and lymphocytes in the diagnostic samples were compared using the Wilcoxon signed-rank test. 17 A Bonferroni correction 18 was used to adjust for multiple testing. The overall type I error rate was set at 10%, and the significance level for an individual comparison was 0.014. The remission samples were analyzed in an exploratory manner, due to the small sample size. The sign test was used to compare the differences between normal myeloid progenitors and lymphocytes and between leukemic blasts and normal myeloid progenitors. A correlation matrix was calculated to assess the relationship between mean channel fluorescence of leukemic blasts, in pairs of antigens among the diagnostic samples, and, separately, for the normal myeloid progenitors in the remission samples. A correlation coefficient greater than 0.90 was taken to indicate a high degree of correlation.
Results
Patient population
The age of the 12 male and 13 female newly diagnosed AML patients included in this study ranged from 26 to 81 (median 52) years. Twenty-two patients had de novo AML; three patients had secondary AML. Seven patients had a favorable karyotype (six had t(15;17) and one had inv (16) 
HLA class I antigen expression at diagnosis
To control for the effects of cryopreservation and thawing, cells from three patients were studied both fresh (on the day of collection) and following cryopreservation. Cryopreserv- ation had no effect on the percentage of cells with HLA class I antigen expression nor on the intensity of staining with anti-HLA class I mAb (data not shown). Therefore, cryopreserved cells were stained with mAb recognizing monomorphic and locus-specific determinants of HLA class I antigens. Furthermore, samples from 12 HLA-A2-positive patients were stained with mAb against HLA-A2, A28 mAb, KS1, and samples from seven HLA-B7-positive patients were stained with anti-HLA-B7 cross-reacting group mAb KS4. Table 1 shows the mean channel fluorescence values for leukemic blasts and for lym- phocytes in the diagnostic samples along with the medians and the ranges of the differences. Increased mean channel fluorescence on the leukemic blasts as compared to autologous lymphocytes was found with anti-HLA-A, anti-HLA-A2, A28, anti-HLA-B and anti-HLA-B7 cross-reacting group mAb in cells from all but one patient. The latter demonstrated reduced staining of the leukemic blasts as compared to autologous lymphocytes. This patient was also the only one with reduced staining with anti-HLA-class I antigen mAb, TP25.99, and anti-␤ 2 M mAb, NAMB1. Figure 1 illustrates the results for Table 2 Comparison of the mean channel fluorescence for HLA class I antigen expression between non-leukemic normal myeloid myeloid progenitors and autologous lymphocytes at remission (n = 8)
Monoclonal
Antigen The median fluorescence intensity for each antibody on normal myeloid progenitors and lymphocytes are compared. b Numbers represent the mean channel fluorescence of the normal myeloid progenitors minus the mean channel fluorescence of the autologous lymphocytes for each patient. Mean channel fluorescence was determined at a resolution of 128.
Table 3
Comparison of HLA class I expression on the surface of paired leukemic and non-leukemic normal myeloid progenitors (n = 8) The median fluorescence intensity for each antibody on leukemic blasts and normal myeloid progenitors are compared. b Numbers represent the mean channel fluorescence of the leukemic blasts minus the mean channel fluorescence of the paired nonleukemic normal myeloid progenitor cells for each patient. Mean channel fluorescence was determined at a resolution of 128.
this sample. We asked whether the increased expression of HLA class I antigens on leukemic blasts compared to autologous lymphocytes was a lineage-specific phenomenon. The mean channel fluorescence of HLA class I antigens on the non-leukemic normal myeloid progenitors was compared to that on autologous lymphocytes (Table 2 ). Mean channel fluorescence was higher on the non-leukemic normal myeloid progenitors than on the autologous lymphocytes, for all HLA class I antigens. We then compared mean channel fluorescence of the paired (by patient), leukemic (collected at diagnosis) and non-leukemic normal myeloid progenitors (collected at remission) for the eight patients for whom both samples were collected. This exploratory analysis yielded no statistically significant differences in any of these comparisons (Table 3) . These results suggest that HLA class I antigen expression is higher on myeloid cells (leukemic and non-leukemic) than on lymphoid cells.
There was a high degree of correlation between the staining by mAb TP25.99 recognizing a monomorphic determinant of HLA class I antigen and that with anti-␤ 2 M mAb NAMB1. The correlation coefficients for these two antigens were 0.95 (95% confidence interval, 0.89 to 0.97) in the diagnostic samples, and 0.94 (95% confidence interval, 0.70 to 0.99) in the Leukemia remission samples. This suggests that ␤ 2 M is mostly, if not exclusively, bound to HLA-A, B, C and E heavy chains on the cell surface membrane of leukemic cells, since the determinant recognized by mAb TP25.99 is restricted to these molecules. Table 4 shows a comparison of the mean channel fluorescences of the leukemic blasts and the lymphocytes in the relapse samples. Loss of HLA class I antigen expression was not detected in any relapse samples.
HLA class I antigen expression by leukemic cells at relapse
Discussion
Indirect immunofluorescence staining with mAb to monomorphic locus-specific and polymorphic determinants of HLA class I antigens did not detect HLA class I antigen downregulation in 24 of the 25 AML samples analyzed at diagnosis. Fur- Table 4 Comparison of the medians of the mean channel fluorescence between leukemic blasts and autologous lymphocytes at relapse (n = 6) thermore, HLA class I antigen downregulation was not found in any of the five relapse samples. Our findings differ from those of Richiardi et al who tested AML cells with alloantisera in a complement-dependent cytotoxic assay 2 or with one anti-HLA class I mAb in indirect immunofluorescence. 3 There are several possible reasons for the discrepancy between Richiardi et al's findings and ours. The loss of HLA class I antigens found by Richiardi et al using the complement-dependent cytotoxic assay may be caused by mechanism(s) distinct from loss of HLA class I molecules, such as resistance of target cells to complement-dependent lysis. Moreover, the negative results which Richiardi et al obtained by indirect immunofluorescence staining with one anti-HLA class I mAb may reflect the loss of the corresponding determinant and not that of the molecules, since selective loss of HLA class I determinants has been described in malignant cells.
HLA class I antigen loss has been reported in many solid tumors. 1 The frequency of HLA class I antigen downregulation in primary lesions of solid tumors varies between 16 and 50%. It is highest in prostate (50%) and breast (43%) cancer and lowest in malignant melanoma (16%). 1 It is unclear why there is a difference in the frequency of HLA class I downregulation among the various types of carcinomas. Though technical problems were suggested, other possibilities such as differences in the rate of mutations and differences in immunoselection are possible as well. 1 One possible explanation for the difference between the frequency of HLA class I antigen downregulation in AML and malignant melanoma as compared to prostate and breast cancer is that AML and malignant melanoma have a relatively short pre-clinical period as compared to tumors such as prostate or breast cancer. It is possible that the rapid presentation of these tumors does not allow enough time for the occurrence of HLA class I downregulation resulting from mutations or immunoselection of the tumor cells.
Another possible explanation for the discrepancy between AML and solid tumors with respect to loss of HLA antigen expression might be that T cells are not involved in immune regulation of AML. However, this possibility is not compatible with the large body of literature demonstrating that T cell depletion of donor marrow is associated with a loss of graftversus-leukemia activity and, consequently, a higher relapse rate following allogeneic transplantation. 19, 20 Furthermore, donor T lymphocyte infusion has been shown to restore complete remission in AML patients who relapse following allogeneic transplantation, albeit infrequently. 21, 22 Thus, preservation of HLA class I antigen expression in AML is not explained by irrelevance of these antigens with respect to immune response to AML cells.
In summary, our work suggests that HLA class I antigen expression is preserved on AML blasts. Therefore, altered expression of these antigens should not be an obstacle in the application of T cell-based immunotherapy in the treatment of AML.
